Rockefeller Capital Management
ALGS icon

Rockefeller Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Rockefeller Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.3K Hold
10,000
– – ﹤0.01% 3041
2025
Q4 		$93.2K Buy
10,000
+9,000
+900% +$84.9K ﹤0.01% 2762
2025
Q3 		$9.8K Buy
+1,000
New +$9.14K ﹤0.01% 3654
2022
Q4 		– Sell
-3,100
Closed -$85K – 3823
2022
Q3 		$85K Buy
+3,100
New +$103K ﹤0.01% 2075

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Rockefeller Capital Management's ALGS Position: Q1 2026 in Review

Rockefeller Capital Management held its Aligos Therapeutics (ALGS) position steady in Q1 2026 at 10,000 shares worth $74.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3041.

Rockefeller Capital Management first reported a position in ALGS in Q3 2022 and has held it in 4 quarters since. The position peaked at $93.2K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Rockefeller Capital Management held 10,000 shares of Aligos Therapeutics worth $74.3K as of Q1 2026.
  • Rockefeller Capital Management left its Aligos Therapeutics share count unchanged in Q1 2026.
  • Aligos Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3041 holding.
  • Rockefeller Capital Management first reported a position in Aligos Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Aligos Therapeutics position peaked at $93.2K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.